Quantum Genomics Announces the Publication of a New Scientific Article in the Journal Hypertension
May 10, 2019 09:47 ET
|
Quantum Genomics
PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Announces the Publication of its Phase IIb NEW-HOPE Study Results of Firibastat in Arterial Hypertension in the Journal Circulation
April 26, 2019 08:00 ET
|
Quantum Genomics
PARIS and NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure
April 17, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, April 17, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Reports Full-Year 2018 Financial Results
March 28, 2019 13:00 ET
|
Quantum Genomics
A 2018 fiscal year marked by significant progress in the following research programs:-- Arterial hypertension: highly significant efficacy of firibastat demonstrated in completed Phase IIb trial,...
Quantum Genomics Announces Positive Results from New Preclinical Studies on Firibastat
March 20, 2019 13:00 ET
|
Quantum Genomics
PARIS and NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company announces positive results from preclinical reproductive...
Quantum Genomics Completes Enrollment in Its Pharmacokinetic Clinical Study of Firibastat
February 25, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure
February 06, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Presents its 2019 Corporate Action Plan
January 31, 2019 13:12 ET
|
Quantum Genomics
PARIS, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...
Quantum Genomics has joined the Pass French Tech program
February 23, 2017 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical...
Quantum Genomics announces 2016 first-half financial results and first nine months business update
October 13, 2016 12:00 ET
|
Quantum Genomics
Sound balance sheet: €13.2 M cash and no financial debt at 30 June18-month financial visibilityPARIS and NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 -...